Table 1.
Assessment of baseline parameters.
| Variable | Group 1 (triple therapy) (n = 298) | Group 2 (dual therapy) (n = 466) |
p value |
|---|---|---|---|
| Sex (male) | 151 (50.5%) | 217 (46.5%) | 0.198 |
| Diabetes mellitus type II | 98 (33.0%) | 135 (28.9%) | 0.158 |
| COPD* | 62 (20.9%) | 101 (21.6%) | 0.786 |
| Hypertension | 254 (85.3%) | 389 (83.4%) | 0.440 |
| Obesity | 97 (32.5%) | 149 (31.9%) | 0.858 |
| Ischemic cardiomyopathy | 174 (58.4%) | 286 (61.4%) | 0.304 |
| Angina pectoralis | 114 (38.2%) | 178 (38.2%) | 0.808 |
| Asthma | 32 (10.6%) | 46 (9.9%) | 0.756 |
| Hypertriglyceridemia | 147 (49.2%) | 210 (45.1%) | 0.188 |
| Increased low density lipoprotein | 172 (57.7%) | 245 (52.6%) | 0.099 |
| Dyslipidemia | 140 (46.9%) | 206 (44.1%) | 0.374 |
| Atherosclerosis | 60 (20.1%) | 100 (21.4%) | 0.643 |
*Chronic obstructive pulmonary disease.